Jacobs Levy Equity Management
KYTX icon

Jacobs Levy Equity Management’s Kyverna Therapeutics KYTX Stock Holding History

Jacobs Levy Equity Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,599
Closed -$143K – 1098
2026
Q1 		$143K Sell
16,599
-91,935
-85% -$766K ﹤0.01% 933
2025
Q4 		$1.02M Sell
108,534
-39,178
-27% -$291K ﹤0.01% 679
2025
Q3 		$886K Buy
+147,712
New +$591K ﹤0.01% 740
2025
Q1 		– Sell
-461,959
Closed -$1.73M – 1215
2024
Q4 		$1.73M Buy
461,959
+442,090
+2,225% +$2.12M 0.01% 623
2024
Q3 		$97.2K Buy
+19,869
New +$153K ﹤0.01% 934

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Jacobs Levy Equity Management's KYTX Position: Q2 2026 in Review

Jacobs Levy Equity Management sold out of Kyverna Therapeutics (KYTX) in Q2 2026, closing a stake of 16,599 shares — an estimated $143K sold.

Jacobs Levy Equity Management first reported a position in KYTX in Q3 2024 and held it in 5 quarters. The position peaked at $1.73M in Q4 2024. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Jacobs Levy Equity Management reported no remaining Kyverna Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 16,599 Kyverna Therapeutics shares in Q2 2026, an estimated $143K.
  • Jacobs Levy Equity Management first reported a position in Kyverna Therapeutics in Q3 2024 and held it in 5 quarters.
  • Jacobs Levy Equity Management's Kyverna Therapeutics position peaked at $1.73M in Q4 2024.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.